SILO 10-Q filed 2026-11-13 | Key takeaways
SILO filed its 10-Q; the most relevant disclosure change is expanded Customer concentration: One customer accounted for 100% of license fee revenue in the nine months ended September 30, 2026; the mutual termination of the sublicense agreement with Aikido Pharma Inc. on September 2, 2026 resulted in zero revenue during Q3 2026 and recorded a $703,552. Customer concentration: Customer One (Aikido Pharma Inc.) represented 100% of revenue.
Key takeaways
Revenue concentration: One customer accounted for 100% of license fee revenue in the nine months ended September 30, 2026; the sublicense termination resulted in zero Q3 2026 revenue.
Net loss narrowed: Q3 2026 loss of $358,743 improved from $1,110,438 in Q3 2025; nine-month loss of $2,838,689 compared favorably to $3,346,168 in the prior-year period.
Capital raise completed: July 2026 private placement raised $4.0 million gross ($3.48 million net) through common stock, pre-funded warrants, and Series A-3/A-4 warrants; November 2026 private placement raised approximately $815,000 net.
Stock repurchase active: Board authorized $1.0 million repurchase plan on February 20, 2026; 20,543 shares held in treasury at September 30, 2026 with cost basis of $44,775.
Authorized shares expanded: Shareholders approved increasing authorized common stock from 6,666,667 to 250,000,000 shares on August 14, 2026, following a 1-for-15 reverse stock split effective June 2, 2026.
Subsidiary formed: Kloneintel LLC (70%-owned) formed on November 3, 2026 to operate KLONE software assets acquired from Norsight Consulting Inc. for a warrant to purchase 300,000 shares valued at $381,242.
Asset purchases recorded: Three software asset purchases during 2026—Many Ads ($714,000 for qwikagents.com assets), Parkview ($506,550 for reputation endpoints software), and Norsight ($381,242 warrant for KLONE platform)—all expensed as R&D with no alternative future use.
Key metrics
Customer concentration
Disclosure changes
- Customer concentration
One customer accounted for 100% of license fee revenue in the nine months ended September 30, 2026; the mutual termination of the sublicense agreement with Aikido Pharma Inc. on September 2, 2026 resulted in zero revenue during Q3 2026 and recorded a $703,552 gain on termination in other income.
Complete loss of the company's single revenue-generating customer relationship; the gain on termination partially offsets the operational loss but represents a non-recurring item. - Subsequent events - Kloneintel formation
On November 3, 2026, the company formed Kloneintel LLC (70%-owned subsidiary) to operate KLONE software assets purchased from Norsight Consulting Inc. on October 1, 2026; Kloneintel is a purpose-built SaaS platform that centralizes performance feedback.
New subsidiary formed to commercialize acquired KLONE software; 70% ownership indicates retained economic interest; represents company expansion into SaaS performance feedback market. - Subsequent events - November 2026 Private Placement
On November 6, 2026, the company closed a private placement yielding approximately $815,000 in net proceeds after deducting placement agent fees and offering expenses.
Additional capital raise completed after quarter-end; combined with July 2026 proceeds, total Q3/Q4 2026 gross proceeds of approximately $5 million strengthens balance sheet. - Stockholders' equity - Authorized shares increase
On August 14, 2026, shareholders approved increasing authorized common stock from 6,666,667 to 250,000,000 shares; common stock par value $0.0001; 1,907,560 shares issued and 1,887,017 shares outstanding at September 30, 2026.
Significant increase in authorized shares provides flexibility for future equity offerings; dilution potential increased substantially. - Treasury stock
20,543 shares of treasury stock held at September 30, 2026 with cost basis of $44,775; 6,015 shares repurchased and cancelled on August 5, 2026; additional 20,543 shares repurchased during August-September 2026.
Company actively repurchasing shares under $1 million authorized program; reduces shares outstanding and partially offsets dilution from warrant exercises. - Asset purchases - Parkview Agreement
On August 18, 2026, company issued 165,000 shares of common stock (valued at $506,550 or $3.07 per share) to Parkview Consulting LLC for Reputation Endpoints software and related intellectual property; entire consideration expensed as R&D with no alternative future use; shares subject to 12-month lock-up.
Third software asset acquisition in 2026; all three expensed as R&D due to lack of alternative future use; reflects company strategy to build AI and software capabilities through asset acquisitions.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow SILO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.